Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
Aditum Bio will fund Kalexo Bio, and both companies will collaborate to advance 2MW7141 into clinical trials.
Therapy Area
GSK plans $30bn investment for R&D in US
Reunion Neuroscience expands Series A to $133m after positive trial milestones
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Podcast: key trials and trends from ESC Congress 2025
AbbVie extends Rinvoq exclusivity by four years after generics settlements
Sanofi’s Tzield gains approval in China for T1D management
